The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acq - P2P | Acquired

Total Raised




About Ambit Biosciences

Ambit Biosciences is a biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is under clinical investigation in patients with relapsed or refractory AML and treatment-naive AML. Ambit is developing quizartinib in collaboration with Astellas Pharma as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Ambit Biosciences Headquarter Location

4215 Sorrento Valley Blvd.

San Diego, California, 92121,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ambit Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ambit Biosciences is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Ambit Biosciences Patents

Ambit Biosciences has filed 33 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Experimental cancer drugs, Clusters of differentiation, Autoimmune diseases, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Transcription factors, Experimental cancer drugs, Clusters of differentiation, Autoimmune diseases, Monoclonal antibodies



Latest Ambit Biosciences News

Acute Myeloid Leukemia Global Market Report 2022

Jul 1, 2022

Major players in the acute myeloid leukemia market are Pfizer Inc. , Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb, Amgen Inc. , Celgene Corporation, and Ambit Biosciences Corporation, Takeda Pharmaceuticals. July 01, 2022 09:14 ET Lyon, FRANCE New York, July 01, 2022 (GLOBE NEWSWIRE) -- announces the release of the report "Acute Myeloid Leukemia Global Market Report 2022" - The global acute myeloid leukemia market is expected to grow from $1.02 billion in 2021 to $1.15 billion in 2022 at a compound annual growth rate (CAGR) of 12.3%. The acute myeloid leukemia market is expected to grow to $1.84 billion in 2026 at a CAGR of 12.5%. The acute myeloid leukemia market consists of the sales of acute myeloid leukemia treatments services by entities (organizations, partnerships, and sole proprietors) that is a cancer of the blood and bone marrow in which a bone marrow cell changes in its genetic material or DNA.It has various adverse health effects as it affects a group of blood cells called the myeloid cells and is most common in adults age 65 and older. General signs and symptoms of the early stages of acute myelogenous leukemia include bone pain, frequent infections, pale skin, unusual bleeding like nosebleeds, and bleeding from the gums. The main acute myeloid leukemia treatment types include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy.Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in the body. The different acute myeloid leukemia chemotherapies include cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, and hormonal therapy.They are of various regimens such as DC regimen, AVD regimen, and VCD regimen. Acute myeloid leukemia is treated by different end-users such as hospitals, retail drug stores, ambulatory care centers, and clinics. North America was the largest region in the acute myeloid leukemia market in 2021. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The acute myeloid leukemia market research report is one of a series of new reports that provides acute myeloid leukemia market statistics, including acute myeloid leukemia industry global market size, regional shares, competitors with a acute myeloid leukemia market share, detailed acute myeloid leukemia market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. This acute myeloid leukemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The increase in the older population base and growing unmet healthcare needs is expected to propel the growth of the acute myeloid leukemia market over the coming years.The geriatric population and growing unmet healthcare are defined as the elderly population, people aged 65 and over suffering from health issues like acute myeloid leukemia. For instance, according to the American Cancer Society USA (ACS), a nationwide voluntary health organization, in 2019, AML was commonly found in elderly people with an average age at diagnosis being 68, and survival of elderly AML patients remained remarkably low.It affected approximately 20,000 people in 2019. Therefore, the geriatric population base and growing unmet healthcare needs drive the gelatin market. Growing investments in R&D using the pharmaceutical groups are a key trend gaining popularity in the acute myeloid leukemia market.R&D is used to develop new and improved products and services to fulfill the needs of drug development. For instance, in April 2020, the Poland based biopharmaceutical company, Ryvu partnered with Italian pharmaceutical company, Menarini and completed the Phase I part of the Phase I/II trial in acute myeloid leukemia (AML) and presented the first-ever data with an in-house developed asset. In March 2020, Gilead Sciences, Inc an American biopharmaceutical company acquired Forty-Seven, Inc. for $95.50 per share in cash which values Forty-Seven at approximately $4.9 billion. The acquisition will strengthen Gilead’s immuno-oncology research and development portfolio due to the addition of Forty Seven’s investigational lead product candidate, Magrolimab. Magnolia is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Forty-Seven is a US based clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

  • When was Ambit Biosciences founded?

    Ambit Biosciences was founded in 2000.

  • Where is Ambit Biosciences's headquarters?

    Ambit Biosciences's headquarters is located at 4215 Sorrento Valley Blvd., San Diego.

  • What is Ambit Biosciences's latest funding round?

    Ambit Biosciences's latest funding round is Acq - P2P.

  • How much did Ambit Biosciences raise?

    Ambit Biosciences raised a total of $214.53M.

  • Who are the investors of Ambit Biosciences?

    Investors of Ambit Biosciences include Daiichi Sankyo, Forward Ventures, MedImmune Ventures, Gimv, GrowthWorks and 14 more.

  • Who are Ambit Biosciences's competitors?

    Competitors of Ambit Biosciences include Sierra Oncology, VIVUS, LeadScope, Array Biopharma, Innate Pharma, ARIAD Pharmaceuticals, KemPharm, Maxygen, Crux Biomedical, Trimeris and 14 more.

You May Also Like

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Pique Therapeutics

Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.


CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.


Oraceuticals uses biotechnologies to develop drugs that advance oral treatment and improve oral health. Focuses on producing bioactive molecules that target chronic oral infections and control inflammation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.